The Additional Polycyclo Ring System Is A Bicyclo Ring System Having Nitrogen As The Only Ring Hetero Atom [e.g., 5-(indolyl-3-methylene)- Hydantoin, Etc.] Patents (Class 548/312.1)
-
Patent number: 6482951Abstract: Isoindolin-1-one-substituted propionamide glucokinase activators which increase insulin secretion in the treatment of type II diabetes.Type: GrantFiled: December 6, 2001Date of Patent: November 19, 2002Assignee: Hoffmann-La Roche Inc.Inventor: Kevin Richard Guertin
-
Patent number: 6476234Abstract: The invention provides improved and simplified methods of synthesizing ligands containing a heteroatom-bearing bridge using a novel intermediate compound. The ligands may be used to form metal complexes that are useful in diagnostic and therapeutic applications.Type: GrantFiled: March 1, 2002Date of Patent: November 5, 2002Assignee: Bracco International B.V.Inventor: Kondareddiar Ramalingam
-
Patent number: 6472526Abstract: The present invention relates to a novel imidazole derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof, in which A, n1 and Y are defined in the specification; to a process for preparation of the compound of formula (1); to intermediates which are used in the preparation of the compound of formula (1): and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.Type: GrantFiled: December 3, 2001Date of Patent: October 29, 2002Assignee: LG Chemical Ltd.Inventors: Hyun Il Lee, Jong Sung Koh, Jin Ho Lee, Won Hee Jung, You Seung Shin, Hyun Ho Chung, Jong Hyun Kim, Seong Gu Ro, Tae Saeng Choi, Shin Wu Jeong, Tae Hwan Kwak, In Ae Ahn, Hyun Sung Kim, Sun Hwa Lee, Kwi Hwa Kim, Jung Kwon Yoo
-
Patent number: 6465500Abstract: Compounds of the formula where W is n is 0, 1, or 2; m is 0, 1, 2, or 3: Y and G are each independently oxygen or sulfur; Z is —O—, —S—, —NH, or —CH2; R1 is hydrogen, C1 to C8 alkyl, substituted C1 to C8 alkyl substituted with one hydroxy, C3 to C8 alkenyl, C3 to C8 alkynyl, aryl, C1 to C3 alkylaryl, C1 to C3 alkylheteroaryl, or —Q—R4; R2 and R3 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkylaryl, or C1 to C3 alkylheteroaryl; R4 is cyano, trifluoromethyl, —COR3, —CO2R8, —CONR9R10, —OR3, —SO2NR9R10, or —S(O)4R9; R9 and R10 are each independently hydrogen, C1 to C8 alkyl, C1 to C3 alkylaryl, aryl, or R9 and R10 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; Q is C1 to C3 alkyl; R11 is hydrogen, —OR12, or —NHCOR12; R12 is hydrogen, C1 to C6 alkyl, aryl, or C1 to C3 alkType: GrantFiled: October 23, 2000Date of Patent: October 15, 2002Assignee: Pfizer Inc.Inventors: John Eugene Macor, Martin James Wythes
-
Publication number: 20020147317Abstract: Disclosed are novel coumarin based fluorogenic compounds useful in assaying for biological activity. Specifically, these fluorogenic compounds exhibit fluorescence at particular wavelengths when cleaved by target enzymes. Preferred compounds include sugar and peptide derivatives of umbelliferone derivatives bearing a heterocyclic five membered ring at the 3-position. These compounds can be used for rapidly detecting food pathogens and for determining sterilization effectiveness. The compounds may also be used in a form bounded to a polymeric support or to a biomolecule or macromolecule.Type: ApplicationFiled: March 11, 2002Publication date: October 10, 2002Applicant: 3M Innovative Propeties CompanyInventors: James Gregory Bentsen, Christopher Allen Mickelson, Orlin Bruce Knudson, Kevin Michael Lewandowski
-
Publication number: 20020143190Abstract: The invention provides improved and simplified methods of synthesizing ligands containing a heteroatom-bearing bridge using a novel intermediate compound. The ligands may be used to form metal complexes that are useful in diagnostic and therapeutic applications.Type: ApplicationFiled: March 1, 2002Publication date: October 3, 2002Inventor: Kondareddiar Ramalingam
-
Patent number: 6448286Abstract: The current invention discloses useful pharmaceutical compositions containing amidino derivative useful as nitric oxide synthase inhibitors.Type: GrantFiled: July 28, 1998Date of Patent: September 10, 2002Assignee: G.D. Searle & Co.Inventors: Donald W. Hansen, Jr., Mark G. Currie, E. Ann Hallinan, Kam F. Fok, Timothy J. Hagen, Arija A. Bergmanis, Steven W. Kramer, Len F. Lee, Suzanne Metz, William M. Moore, Karen B. Peterson, Barnett S. Pitzele, Dale P. Spangler, R. Keith Webber, Mihaly V. Toth, Mahima Trivedi, Foe S. Tjoeng
-
Patent number: 6410562Abstract: This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.Type: GrantFiled: December 8, 2000Date of Patent: June 25, 2002Assignee: Eli Lilly and CompanyInventors: Michael R. Jirousek, Michael Paal, Gerd Ruhter, Theo Schotten, Kumiko Takeuchi, Wolfgang Stenzel
-
Patent number: 6410739Abstract: Compounds of the formula where W is are particularly useful in treating migraine and other disorders, such as depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders. The compounds can also be used as centrally acting antihypertensives and vasodilators.Type: GrantFiled: October 23, 2000Date of Patent: June 25, 2002Assignee: Pfizer INCInventors: John Eugene Macor, Martin James Wythes
-
Patent number: 6395764Abstract: This invention involves compounds having the following structure: wherein: a) R1 is hydrogen; or alkyl; bond (a) is a single or a double bond; b) R2 and R3 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino and halo; c) R4, R5 and R6 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino; halo; and 2-imidazolinylamino; and wherein one and only one of R4, R5 and R6 is 2-imidazolinylamino; d) R7 is selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino and halo;Type: GrantFiled: October 17, 2000Date of Patent: May 28, 2002Assignee: The Procter & Gamble CompanyInventors: Raymond Todd Henry, Russell James Sheldon, William Lee Seibel
-
Patent number: 6388090Abstract: An imidazole derivative of formula (I) or a pharmaceutically acceptable salt or derivative thereof. The compounds of formula I exhibit affinity for alpha2 adrenoceptors.Type: GrantFiled: January 12, 2001Date of Patent: May 14, 2002Assignee: Orion CorporationInventors: Paavo Huhtala, Arto Karjalainen, Antti Haapalinna, Jyrki Lehtimäki, Arja Karjalainen, Raimo Virtanen
-
Patent number: 6387937Abstract: Compounds of the formula where W is n is 0, 1, or 2; m is 0, 1, 2, or 3: Y and G are each independently oxygen or sulfur; Z is —O—, —S—, —NH, or —CH2; R1 is hydrogen, C1 to C8 alkyl, substituted C1 to C8 alkyl substituted with one hydroxy, C3 to C8 ; alkenyl, C3 to C8 alkynyl, aryl, C1 to C3 alkylaryl, C1 to C3 alkylheteroaryl, or —Q—R4; R2 and R3 are each independently hydrogen, Cl1 to C8 alkyl, aryl, C1 to C3 alkylaryl, or C1 to C3 alkylheteroaryl; R4 is cyano, trifluoromethyl, —COR8, —CO2R9, —CONR9R10, —OR8, —SO2NR8R10, or —S(O)4R9; R9 and R10 are each independently hydrogen, C1 to C8 alkyl, C1 to C3 alkylaryl, aryl, or R9 and R10 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; Q is C1 to C3 alkyl; R11 is hydrogen, —OR12, or —NHCOR12; R12 is hydrogen, C1 to C4 alkyl, aryl, or C1 to C3Type: GrantFiled: October 23, 2000Date of Patent: May 14, 2002Assignee: Pfizer Inc.Inventors: John Eugene Macor, Martin James Wythes
-
Patent number: 6384284Abstract: A description is given of diphenyl compounds of formula wherein R is a camphor or hydantoin derivative; and R1 is hydrogen; or C1-C5alkyl. These compounds are suitable as light stabilizers in cosmetic, pharmaceutical and veterinary formulations.Type: GrantFiled: March 29, 2001Date of Patent: May 7, 2002Assignee: Ciba Specialty Chemicals CorporationInventors: Rudolf Zink, Dieter Reinehr, Helmut Luther, Bernd Herzog
-
Publication number: 20020052368Abstract: Novel compounds of formula I: 1Type: ApplicationFiled: March 26, 2001Publication date: May 2, 2002Inventors: Charles K. Marlowe, Kim A. Kane-Maguire, Bing-Yan Zhu, Robert M. Scarborough
-
Publication number: 20020049239Abstract: This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: ApplicationFiled: September 28, 2001Publication date: April 25, 2002Applicant: SYNAPTIC PHARMACEUTICAL CORPORATIONInventors: Yoon T. Jeon, Charles Gluchowski
-
Patent number: 6369076Abstract: Novel 5-benzyl-octahydroindoles and 6-benzyl-decahydroquinolines substituted in the 1-position are effective as NMDA NR2B antagonists useful for relieving pain.Type: GrantFiled: October 25, 2000Date of Patent: April 9, 2002Assignee: Merck & Co. Inc.Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson
-
Patent number: 6358993Abstract: The present invention relates to pharmaceutically acceptable compounds, including certain substituted indolinyl and derivatives thereof, 1,2,3,4-tetrahydroquinolinyl and derivatives thereof, 1,2,3,4-tetrahydroisoquinolinyl, benz[cd]indolinyl and 5,6-dihydrophenanthridinyl compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of neurological injury and neurodegenerative disorders.Type: GrantFiled: October 22, 1999Date of Patent: March 19, 2002Assignee: CeNes Pharmaceuticals, Inc.Inventors: N. Laxma Reddy, Michael Maillard, David Berlove, Sharad Magar, Graham J. Durant
-
Publication number: 20020028840Abstract: The present invention relates to novel imidazoly 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.Type: ApplicationFiled: July 6, 2001Publication date: March 7, 2002Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, G. Davis Harris
-
Publication number: 20020025948Abstract: Compounds of formula I, 1Type: ApplicationFiled: June 18, 2001Publication date: February 28, 2002Inventors: Bernard Joseph Banks, Douglas James Critcher, Ashley Edward Fenwick, David Morris Gethin, Stephen Paul Gibson
-
Patent number: 6346625Abstract: The present invention relates to compounds of formula (I) wherein: Ar1 or Ar2 is an optionally substituted indole, and the other group is an optionally substituted aromatic or heteroaromatic group, preferably an optionally substituted indole, X is O or S, and R2 is H, hydroxy, amino, C1-6alkyl, hydroxyC1-6alkyl or aminoC1-6alkyl, and salts and solvates thereof and solvates of such salts, and the use of such compounds in medical therapies.Type: GrantFiled: October 25, 1999Date of Patent: February 12, 2002Assignee: AstraZeneca ABInventors: Kostas Karabelas, Matti Lepistö, Peter Sjö
-
Patent number: 6342516Abstract: Phenylazole compounds represented by general formula (1) or pharmaceutically acceptable salts thereof and drugs for hyperlipemia which contain these compounds as the active ingredient, wherein A represents imidazolyl, pyrazolyl, etc.; B represents (1a) or (1b) (wherein R2 and R3 represent each hydrogen, C1-6 alkyl, etc; and k is 0 or an integer of 1 to 15); Y represents O, S, a bond, etc.; and Z represents an optionally substituted and saturated or unsaturated heterocycle containing 1 to 4 N, O or S atoms. Among all, compounds wherein Z is substituted chroman-2-yl, 2,3-dihydrobenzofuran-2-yl, etc. have an effect of inhibiting the formation of lipid peroxides too.Type: GrantFiled: January 26, 2001Date of Patent: January 29, 2002Assignee: Nippon Soda Co., Ltd.Inventors: Nobuhiro Umeda, Nobuo Mochizuki, Seiichi Uchida, Tadayuki Nishibe, Hirokazu Yamada, Kunihito Ito, Hiromi Horikoshi
-
Patent number: 6337342Abstract: The present invention relates to compounds of formula (I): wherein: Ar is an optionally substituted aromatic or heteroaromatic group, R1 is H, C1-6alkyl, CF3, phenyl, benzyl, carboC1-6alkoxy, carbamoyl, or methyl(N—C1-6alkylcarbamoyl) R2 is H, C1-6alkyl, aminoC1-6alkyl, hydroxyC1-6alkyl, (mono- or di- C1-6alkyl)aminoC1-6alkyl, (aminoC1-3alkylphenyl)C1-3alkyl, amidinothio C1-6alkyl, R3 is H or C1-6alkoxy, R4 is H or together with R2, forms an annulated ring which may be substituted by hydroxyC1-3alkyl or amidinothio C1-3alkyl, or aminoC1-3alkyl; and pharmaceutically acceptable salts thereof; and the use of such compounds in medical therapies.Type: GrantFiled: January 29, 1999Date of Patent: January 8, 2002Assignee: AstraZeneca ABInventors: Kostas Karabelas, Matti Lepisto, Peter Sjö
-
Publication number: 20010056109Abstract: An imidazole derivative of formula (I) 1Type: ApplicationFiled: January 12, 2001Publication date: December 27, 2001Inventors: Paavo Huhtala, Arto Karjalainen, Antti Haapalinna, Jyrki Lehtimaki, Arja Karjalainen, Raimo Virtanen
-
Patent number: 6333323Abstract: A compound of the formula: wherein R1 is hydrogen, lower alkyl, or optionally substituted arylsulfonyl, or the like, R2 is hydrogen, lower alkyl, or optionally substituted aralklyl, or the like, R3, R4, R5, and R6 each is independently hydrogen, halogen, trihalogenated lower alkyl, or the like, X is hydroxy or optionally substituted amino, Y is COOR R is hydrogen or an ester residue), optionally substituted aryl, or optionally substituted heteroaryl, has integrase inhibition activity, and is useful as an anti-HIV drug.Type: GrantFiled: August 18, 2000Date of Patent: December 25, 2001Assignee: Shionogi & Co., Ltd.Inventors: Toshio Fujishita, Tomokazu Yoshinaga
-
Publication number: 20010051637Abstract: A method for the prophylaxis or treatment of conditions for which 5-HT1-like agonists are indicated comprising the administration of therapeutically-effective amount of compounds of formula (I) 1Type: ApplicationFiled: January 12, 2001Publication date: December 13, 2001Inventors: Robert John Blade, Yih Sang Pang, David Lawrence Selwood
-
Patent number: 6323228Abstract: 3-Substituted indole carbohydrazides having the formula are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.Type: GrantFiled: September 15, 2000Date of Patent: November 27, 2001Assignee: Abbott LaboratoriesInventors: Nwe Y. BaMaung, Richard A. Craig, Megumi Kawai, Jieyi Wang
-
Publication number: 20010044547Abstract: Compounds of formula (I), wherein A and A are independently the same or different group of formula (II) wherein: R′ is H, CH3, C(CH3)2,—ORa, —N(Ra)2, —N(Ra)ORa or -DP; R is H or CH3; Ra is H, C1-C3 alkyl; D is a bond, alkylene, —C(═O)—, —S(O)— or S(O)2—; P is an optionally substituted, mono or bicyclic carbo- or hetereocycle; R″ is H, any of the sidechains found in the natural amino acids, carboxacetamide, or a group (CH2)nDP; M is a bond or —C(═O)N(R′″)-; Q is absent, a bond, —CH(OH)— or CH2—; or R″ together with Q, M and R define an optionally substituted 5 or 6 membered carbo- or heterocyclic ring which is optionally fused with a further 5 or 6 membered carbo- or heterocyclic ring; with the proviso that R is —ORa, -, N(Ra)2, —N(Ra)ORa or -DP, if M is a bond and Q is absent; X is H, OH, OCH3, Y is H, OH, OCH3, but X and Y are not both H; Z′ and Z″ are independently —(Type: ApplicationFiled: June 21, 2001Publication date: November 22, 2001Applicant: Medivir ABInventors: Bjorn Classon, Ingemar-Sven-Anders Kvarnstrom, Bengt Bertil Samuelsson
-
Patent number: 6316635Abstract: The present invention relates to novel imidazoly 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.Type: GrantFiled: April 15, 1999Date of Patent: November 13, 2001Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, G. David Harris
-
Patent number: 6313312Abstract: Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances.Type: GrantFiled: December 20, 1999Date of Patent: November 6, 2001Assignee: Pfizer INCInventors: Bernard Joseph Banks, Robert James Crook, Stephen Paul Gibson, Graham Lunn, Alan John Pettman
-
Patent number: 6313310Abstract: Disclosed are 4- and 5-alkynyloxindoles as well as 4- and 5-alkenyloxindoles that inhibit or modulate protein kinases, in particular JNK protein kinases. The compounds of the invention and their pharmaceutically acceptable salts, and prodrugs of said compounds, are useful as anti-inflammatory agents, particularly useful in the treatment of rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing the foregoing compounds, methods for the treatment and/or control of inflammation, particularly in the treatment or control of rheumatoid arthritis using these compounds, as well as intermediates useful in the preparation of compounds of the invention.Type: GrantFiled: December 15, 1999Date of Patent: November 6, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Kin-Chun Luk, Paige E. Mahaney, Steven Gregory Mischke
-
Patent number: 6310067Abstract: Urocanic acid derivatives useful as antiallergic agents represented by the following formula (I) or a pharmacologically acceptable salt thereof: wherein R2 denotes hydrogen or lower alkyl, R3 denotes nitro, amino, cyano or COOR2, wherein R2 in said COOR2 is as defined above, and Q denotes carbon or nitrogen.Type: GrantFiled: August 3, 2000Date of Patent: October 30, 2001Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Kazumi Ogata, Kazuhiko Ito, Takahiro Sakaue, Sachiko Inoue, Shinya Ogino
-
Patent number: 6307056Abstract: Disclosed are 4-aryloxindoles that inhibit or modulate protein kinases, in particular JNK protein kinases. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are useful as anti-inflammatory agents, particularly useful in the treatment of rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing the foregoing compounds, as well as methods for the treatment and/or control of inflammation, particularly in the treatment or control of rheumatoid arthritis, using said compounds.Type: GrantFiled: December 15, 1999Date of Patent: October 23, 2001Assignee: Hoffman-La Roche Inc.Inventors: Wendy Lea Corbett, Kin-Chun Luk, Paige E. Mahaney
-
Patent number: 6303643Abstract: This invention is directed to indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: October 17, 2000Date of Patent: October 16, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Yoon T. Jeon, Charles Gluchowski
-
Patent number: 6291501Abstract: The subject invention pertains to compounds which are useful as antiinflammatory agents and to compositions containing such compounds as active ingredients. The novel uses of the compounds relate to the anti-neurogenic inflammatory properties of the disclosed bis-heterocyclic compounds. Specifically exemplified herein are dragmacidin f, topsentin d, and topsentin e, and their salts, analogs, and derivatives.Type: GrantFiled: February 19, 1999Date of Patent: September 18, 2001Assignees: Harbor Branch Oceanographic Institution, Inc., Regents of the University of CaliforniaInventors: Amy E. Wright, Shirley A. Pomponi, Robert S. Jacobs
-
Patent number: 6281228Abstract: Novel compounds are provided which are inhibitors of MTP and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases, and have the structure including pharmaceutically acceptable salts thereof, or prodrug esters thereof, A is where Z is N or CH, or where Z is or CH2 when is a single bond; and wherein L1, R, R1, R3, R3′, R3a, R3b, R4, R4′, R5, R5a, X, are as defined herein.Type: GrantFiled: June 14, 1999Date of Patent: August 28, 2001Assignee: Bristol-Myers Squibb CompanyInventor: Joseph A. Tino
-
Patent number: 6281356Abstract: Disclosed are substituted pyrroles having the formula These compounds and their pharmaceutically acceptable salts are useful in the treatment and/or control of cell proliferative disorders, in particular cancer. Also disclosed are pharmaceutical compositions containing the foregoing compounds.Type: GrantFiled: December 15, 2000Date of Patent: August 28, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Nader Fotouhi, Norman Kong, Allen John Lovey
-
Patent number: 6277847Abstract: This invention relates to herbicidal compounds of formula (I), methods of making such herbicidal compounds and methods of using such herbicidal compounds. It has been found that compounds of formula (I) are useful as pre-emergent and post-emergent herbicides. Formula (I) is as follows: where Q, X, Y, n, and R are as described herein. This invention is also directed to intermediates used in the preparation of such herbicidal compounds.Type: GrantFiled: March 30, 2000Date of Patent: August 21, 2001Assignee: FMC CorporationInventors: George Theodoridis, Scott D. Crawford
-
Patent number: 6268363Abstract: The present invention relates to a novel imidazole derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof, in which A, n1 and Y are defined in the specification; to a process for preparation of the compound of formula (1); to intermediates which are used in the preparation of the compound of formula (1); and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.Type: GrantFiled: May 17, 2000Date of Patent: July 31, 2001Assignee: LG Chemical Ltd.Inventors: Hyun Il Lee, Jong Sung Koh, Jin Ho Lee, Won Hee Jung, You Seung Shin, Hyun Ho Chung, Jong Hyun Kim, Seong Gu Ro, Tae Saeng Choi, Shin Wu Jeong, Tae Hwan Kwak, In Ae Ahn, Hyun Sung Kim, Sun Hwa Lee, Kwi Hwa Kim, Jung Kwon Yoo
-
Patent number: 6252086Abstract: Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula and the pharmaceutically acceptable salts thereof. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.Type: GrantFiled: April 14, 2000Date of Patent: June 26, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Yi Chen, Apostolos Dermatakis, Kin-Chun Luk
-
Patent number: 6242422Abstract: This invention is directed to novel (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.Type: GrantFiled: October 22, 1998Date of Patent: June 5, 2001Assignee: Idun Pharmacueticals, Inc.Inventors: Donald S. Karanewsky, Vincent J. Kalish, Edward D. Robinson, Brett R. Ullman
-
Patent number: 6214834Abstract: This invention relates to novel heterocycles which are useful as antagonists of the &agr;v&bgr;3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, to iontophoretic delivery of such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.Type: GrantFiled: March 27, 1998Date of Patent: April 10, 2001Assignee: Dupont Pharmaceuticals CompanyInventors: Prabhakar K. Jadhav, Douglas G. Batt, Munir A. Hussain, William J. Pitts, Arnold J. Repta
-
Patent number: 6211156Abstract: The present invention relates to small peptides that cause penile erections in male animals when injected into the paraventricular nucleus of the hypothalamus or when given systemically (intravenously or subcutaneously) to such animals. These peptides are useful in the treatment of erectile dysfunction.Type: GrantFiled: November 10, 1999Date of Patent: April 3, 2001Assignee: Asta Medica A.G.Inventors: Antonio Argiolas, Romano Deghenghi
-
Patent number: 6174883Abstract: This invention relates to novel 3-substituted-2-oxindole derivatives of the formula and the phamaceutically-accepted salts thereof which are inhibitors of prostaglandin H2 synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-substituted-2-oxindole derivatives; to methods of inhibiting prostaglandin H2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel carboxylic acids useful as intermediates in the preparation of the 3-substituted-2-oxindole derivatives of this invention and to a process for the preparation of the 3-substituted-2-oxindole derivatives.Type: GrantFiled: June 7, 1995Date of Patent: January 16, 2001Assignee: Pfizer Inc.Inventors: Frederick J. Ehrgott, Carl J. Goddard, Gary R. Schulte
-
Patent number: 6175013Abstract: This invention provides a series of substituted 2-imidazolines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these compounds.Type: GrantFiled: June 10, 1994Date of Patent: January 16, 2001Assignee: Eli Lilly and CompanyInventors: Philip A. Hipskind, J. Jeffry Howbert, Brian S. Muehl